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Mammals utilize a single phosphopantetheinyl
transferase for the posttranslational modifica-
tion of at least three different apoproteins: the
carrier protein components of cytosolic and
mitochondrial fatty acid synthases and the ami-
noadipate semialdehyde reductase involved in
lysine degradation. We determined the crystal
structure of the human phosphopantetheinyl
transferase, a eukaryotic phosphopantetheinyl
transferase characterized, complexed with
CoA and Mg2+, and in ternary complex with
CoA and ACP. The involvement of key residues
in ligand binding and catalysis was confirmed
by mutagenesis and kinetic analysis. Human
phosphopantetheinyl transferase exhibits an
a/b fold and 2-fold pseudosymmetry similar to
the Sfp phosphopantetheinyl transferase from
Bacillus subtilis. Although the bound ACP ex-
hibits a typical four-helix structure, its binding
is unusual in that it is facilitated predominantly
by hydrophobic interactions. A detailed mecha-
nism is proposed describing the substrate
binding and catalytic process.
INTRODUCTION
The posttranslational modification of a conserved serine
residue in carrier proteins with a phosphopantetheinyl
moiety transferred from coenzyme A through the enzyme
phosphopantetheinyl transferase (PPT) (Figure 1) is vital to
all living organisms. The resulting holo-carrier proteins
play essential roles as components of fatty acid and poly-
ketide synthases (acyl carrier proteins, ACPs) and nonri-
bosomal peptide synthases (peptidyl carrier proteins,
PCPs) [1]. In addition, phosphopantetheinylated carrier
proteins are also involved in the metabolism of lysine
and tetrahydrofolate [2–4]. In each of these systems, the
reactive sulfhydryl of the flexible 20 A˚-long phosphopante-
theine arm provides a center for the transport of reaction
intermediates between the various catalytic components
of the pathway.Chemistry & Biology 14, 1243–125Whereas microbial genomes contain more than one
PPT [5–8], only one PPT has been identified in mammals.
This enzyme exhibits a broad substrate specificity and is
able to phosphopantetheinylate the ACP components of
the cytosolic and the mitochondrial FAS systems, as
well as aminoadipate semialdehyde dehydrogenase, the
human ortholog to the yeast lys5 gene [2, 9]. Subcellular
fractionation studies indicate that the human PPT is lo-
cated in the cytosolic compartment, implying that the
mitochondrial ACP and aminoadipate semialdehyde de-
hydrogenase undergo posttranslational modification prior
to their import into mitochondria. Molecular cloning and
biochemical characterization of human PPT revealed
that this cytosolic enzyme is a Mg2+-requiring monomeric
enzyme that exhibits a broad acceptor substrate speci-
ficity [9].
Based on sequence motifs and structural features,
phosphopantetheine transferases are classified in three
different groups [6]. Group I is represented by bacterial
transferases of about 120 residues, acting on the ACP
of bacterial FASs with Escherichia coli or Bacillus subtilis
ACPs as prototype members. Structure determination of
the group I PPT (designated as holo-ACP synthase,
AcpS) from B. subtilis and Streptococcus pneumoniae re-
vealed a trimeric arrangement of an a/b fold domain [10,
11]. The active site is located in the cleft between the dif-
ferent subunits, resulting in three active sites per mole-
cule. Group II PPTs are exemplified by the Sfp protein
from B. subtilis, which catalyzes the 40-phosphopante-
theine transfer from CoA to the nonribosomal, PCP do-
main of bacterial surfactin synthetase [7, 12, 13]. Sfp is
a monomer of about 240 residues and exhibits a broader
acceptor substrate specificity than group I PPTs. The
crystallographic analysis of Sfp [13] revealed a two-do-
main enzyme with intrinsic pseudo 2-fold symmetry, how-
ever, with a similar domain architecture as trimeric AcpS.
The 40-phosphopantetheine donor is bound in a cleft
formed by the two domains, and the structure revealed
basic principles of Mg2+ and CoA binding. Group III
PPTs comprise transferases that are an integral part of
the heteromeric yeast and fungal FASs [14], which display
a different architecture than mammalian FAS systems [15–
17]. The group III PPTs appear to act on their apoACP sub-
strates prior to assembly of the megasynthase complex
since, in the context of the complete complex, the PPT
structure is distorted and incapable of binding CoA [16].3, November 2007 ª2007 Elsevier Ltd All rights reserved 1243
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Structure of Human ACP SynthaseFigure 1. Reaction Catalyzed by Human
PPT
A conserved Ser-OH nucleophile in the ACP
acceptor protein is modified through modifica-
tion by the (b-) phosphopantetheinyl group of
CoA to yield holo-ACP.The closest structurally characterized enzyme to human
PPT is the group II Sfp enzyme from B. subtilis (PDB ID:
1QR0 [13]). Here, we describe the structure determination
of apo and substrate complexes and provide biochemical
analysis of human PPT, to our knowledge the first higher
eukaryotic representative of this class of enzymes. These
data suggest a general reaction mechanism for eukaryotic
PPT and, as far as we know, furthermore provide for
the first time structural evidence that type I and II ACPs
distinguish their substrate molecules through distinct
recognition mechanisms.
RESULTS AND DISCUSSION
Overall Structure of Human PPT
Human PPT consists of two nearly identical domains
connected by a short linker region. The two halves super-
impose on each other with an rmsd of 2.4 A˚ but are distin-
guished by two features. First, the N- and C-terminal
regions of the protein contain 16 and 42 residue exten-
sions, respectively, that are unique to each half of the
molecule. Both extensions are well ordered, and only the
terminal four-five residues are indistinguishable from
the noise in the electron density maps. Second, although
the regions encompassing residues 91–116 in the N-termi-
nal domain and residues 207–239 in the C-terminal
domain both fold into a pair of b sheets connected by a
loop region, the extension in the C-terminal domain is
significantly longer (Figure 2).
The overall fold adopted by human PPT most closely
resembles that of the B. subtilis Sfp protein with the
exception of the N- and C-terminal extensions that are
unique to the human enzyme. The C-terminal extension
folds back to the N-terminal domain and possibly fixes
the relative orientation of the domains so that it is optimal
for catalysis. Both the human andB. subtilis enzymes con-
tain a pair of positionally equivalent b sheets looped out
from the core structure in the C-terminal domain: residues
196–227 in PPT and 160–187 in Sfp. However, in Sfp this
region is involved in an extended crystal contact and pro-
trudes from the main body of the protein up to 45 A˚. Reuter1244 Chemistry & Biology 14, 1243–1253, November 2007 ª20et al. [13] have speculated that this region may be involved
in apoprotein binding.
The functional domains can be defined with the help of
the group I PPT AcpS, which consists of a shorter chain
that trimerises to form the functionally active protein.
Superposition of this structure on the N- and C-terminal
domains of human PPT (Figure 2) reveals that N-terminal
13 and the C-terminal 52 residues can be regarded as ex-
tensions and that the linker between the N- and C-terminal
domain consists of a single residue. Another feature is the
disordered loop between residues 248–263, which starts
after the superposition of the PPT C-terminal domain
and AcpS ends, suggesting that this may act as a flexible
linker.
Structure of the Fatty Acid Synthase ACP Domain
and Binding to PPT
ACPs are classified into two distinct groups, type I repre-
senting those that are part of the multifunctional polypep-
tides that constitute the cytosolic animal FAS and modular
polyketide synthases and type II that are associated with
the freestanding enzyme systems involved in fatty acid
and polyketide synthesis in bacteria, plastids, and mito-
chondria. Although several type II ACP structures have
been determined experimentally, only one type I structure
has been solved, that of the rat FAS, using NMR [18]. We
have now determined the structure of human PPT in
complex with CoA and the ACP domain of human FAS
(PDB ID: 2CG5). The serine acceptor residue for the phos-
phopantetheinyl moiety in ACP was mutated to alanine to
facilitate crystallization of a stable ternary complex of
PPT, apoACP, and CoA. Thus, as far as we know, this
study constitutes the first description of a type I ACP mol-
ecule in complex with both CoA and one of its cognate in-
teracting proteins.
The structures of both type II ACPs and peptidyl carrier
proteins superimpose onto that of human cytosolic FAS
ACP with rmsds generally <3 A˚. Whereas the published
type I rat ACP structure determined by NMR (1N8L [18])
shows clear differences in the N-terminal loop segments
(rmsd >5 A˚), a recently deposited rat type I ACP NMR
structure (2PNG) is more similar to human cytosolic ACP07 Elsevier Ltd All rights reserved
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Structure of Human ACP SynthaseFigure 2. Structural Comparison of the PPT Family
(A) Ribbon model of human PPT in complex with CoA and Mg2+ revealing the 2-fold pseudosymmetry of group II PPTs.
(B) Similar view of human PPT rotated 90 around the y axis, CoA electron density (positive difference map, contoured at 2s) displayed in blue. N and C
termini are highlighted in blue and labeled N and C, respectively. The loop with missing electron density is indicated by x.
(C) Overlay between human PPT and bacterial AcpS (trimeric subunits displayed in yellow, cyan, and violet), showing active sites located in the
domain clefts both for group I and II PPTs.
(D) Overlay of group II PPTs (cyan, Bacillus subtilis Sfp; red/green, human PPT).
(E) Structural alignment of human PPT, Sfp, and AcpS highlighting conserved motifs and secondary structure elements. CoA binding residues are
boxed in light blue, catalytic residues in red. One AcpS molecule is included in the alignment to highlight similar secondary structure features. The
structural alignment and the plot were generated with the ICM software package [35], extended strands are depicted in green, alpha helices in
red, and 3/10 helices in purple.with rmsd for a-carbons 2 A˚. As the first structure (1N8L)
is indicated as being a preliminary model, the differences
with the human ACP in the N-terminal region can be
disregarded.Chemistry & Biology 14, 1243–1253Although sequence identities between different ACP
forms are as low as 20%, all ACPs that have been
structurally characterized display a four-helix bundle
arrangement in which the serine residue targeted for, November 2007 ª2007 Elsevier Ltd All rights reserved 1245
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Structure of Human ACP SynthaseFigure 3. ACP Binding to Human PPT
(A) Ribbon model of human PPT (green/red) with ACP (light brown). The mutated Ser/Ala acceptor residue of ACP is indicated in stick representation
(arrow).
(B) Detailed PPT-ACP interactions. ACP is shown as light brown ribbon model with interacting residue side chains (labeled in blue). PPT residues are
depicted as stick models (labeled in black).
(C and D) Local electrostatic potential of the a2 (recognition) helices of human ACP (C) and E. coli ACP (D), calculated with the REBEL module im-
plemented in the ICM software package [36]. Red color indicates negative charge, blue color positive charges, ranging from5 to +5 kcal/e.u. charge
units. The Ser acceptor positions are depicted at the lower left corner of the ACP molecule. Arrows indicate positions of the hydrophobic recognition
patches.phosphopantetheinylation is located on the surface of the
protein at the N terminus of helix-a2 (Figure 3). ACP do-
mains associated with type I fungal FASs deviate slightly
from this pattern in that they consist of two four-helix
subdomains, the second of which carries the postransla-
tionally added phosphopantetheinyl moiety [16, 19].
The type I human ACP binds in the cleft between the two
domains of the PPT and the essential Ser2156Ala points
directly toward the b-phosphate of the bound CoA. The
interaction between the two proteins takes place on a large
interface and is mostly of hydrophobic character. Three
hydrophobic patches on the PPT surface interact with
the ACP. The first is formed by PPT residues Phe51-
Ala54 and interacts with a hydrophobic island formed by
ACP residues Ile2137, Val2143, and Leu2152. The second
consists of the exposed side chain of Leu191 on the PPT
surface and Val2176 on the ACP. Possibly, the hydropho-
bic pantetheinyl of CoA also interacts with this patch as it1246 Chemistry & Biology 14, 1243–1253, November 2007 ª20is pointing toward this direction, but it cannot be located in
the electron density map and therefore has not been mod-
eled. The third hydrophobic interface consists of PPT
residues Phe144-Met148, Phe173, and Trp177 interacting
with ACP residues Leu2157, Met2158, and Val2160. Elim-
ination of this hydrophobic patch by replacement of all
three amino acids with alanine residues decreased the
Km for ACP by at least three orders of magnitude, consis-
tent with a role for the hydrophobic patch in recognition by
the PPT (data not shown). A few polar interactions that
involve hydrogen bonds and salt bridges can be observed
(ACP-PPT: Arg2138-Gly137, Asp2151-Gln50, Thr2165-
Arg138, Glu2169-Arg138), but binding specificity seems
to be determined by shape complementarity rather than
through the few specific interactions.
Although these polar interactions are largely mediated
by residues located on ACP helix a2, which is categorized
for type II ACPs as the ‘‘universal recognition helix’’ [20],07 Elsevier Ltd All rights reserved
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Structure of Human ACP Synthasethe type of recognition clearly is different between type I
and II ACPs. In type II ACPs, highly conserved negatively
charged residues play a dominant role in mediating bind-
ing to their cognate proteins [20–22]. For example, the
ability of the group I E. coli PPT to catalyze phosphopan-
tetheine transfer to heterologous type II ACPs involved in
polyketide synthesis correlates closely with the overall
negative charge on the apo-ACP substrates [23], and
the complex between the Group I B. subtilis PPT and its
cognate type II ACP is stabilized predominantly by hydro-
philic contacts [11]. However, a comparison of the recog-
nition surfaces of type II (E. coli) ACP and type I (human
cytosolic FAS) ACPs reveals a considerably lower overall
negative charge in the human ACP (Figure 3). Based on
analysis of sequence alignments, this feature appears to
be a characteristic of the ACP domains associated with
both the type I fatty acid and polyketide synthases. So, al-
though the positioning of the human ACP in complex with
its cognate PPT is similar to that found in the type II
ACP:AcpS complex (PDB ID: 1F80) and the same helix-
a2 structural element appears to play a key role in this
interaction, hydrophobic residues appear to make a
stronger contribution in the type I systems.
Upon binding the ACP, the two domains of PPT rotate
around a hinge consisting of residue Glu133, and close
slightly (3.9 A˚ at the furthest point from the hinge, or
approximately 10 degrees). This motion is not expected
to have a significant impact on catalysis since the confor-
mation of active-site residues remains nearly identical,
except for Glu138 that is involved in Mg binding; in
the ACP complex, the lack of Mg supposedly lets the
Glu138 side chain rotate into a different position. In the
PPT-CoA complex, the long C-terminal coil of the enzyme
(residues 290–305) is highly ordered due to its participa-
tion in crystal packing with two other subunits in the crys-
tal lattice. For the PPT-CoA-ACP complex, the packing
within the crystal lattice is different, and this region is no
longer visible in the electron density maps, indicating
inherent flexibility. On the other hand, the position of the
bound CoA is changed only slightly on binding of ACP,
and the phosphopantetheine moiety is now disordered,
possibly oriented away from the active site to avoid colli-
sion with the bound ACP. Structures of PPT with CoA
bound show variable position of the pantetheine moiety,
suggesting this part of the molecule does not have a con-
strained conformation [11] (PDB ID: 2jbz). This is also in
agreement with the fact that modified CoAs such as ace-
tyl-CoA can act as substrates for PPT. Surprisingly, in the
PPT-CoA-ACP complex, no density was found for the Mg
that is sequestered in the active center of the PPT-CoA
complex. This may be explained by a water molecule
that coordinates the Mg in the PPT-CoA structure, which
is displaced by the Ala side chain (substituted for the
Ser2156) when complexed with ACP. The b-phosphate
of CoA also moves closer to the acceptor Ser2156Ala
and to the catalytic residue Glu181 (see below). No signif-
icant motion can be detected among the side chains of ac-
tive-site residues (except for Glu181, which is pushed
slightly back by the movement of the b-phosphate ofChemistry & Biology 14, 1243–125CoA), indicating that binding of CoA alone positions
them suitably for catalysis.
CoA and Mg Binding to Human PPT
In the structure of PPT with Mg2+ and CoA (2C43), the
ligands are found in the active site formed in a shallow
groove at the interface of the two domains (Figure 2A),
similar to the binding mode of these ligands determined
for bacterial Sfp [13]. CoA is bound in a bent conformation
with the pyrophosphate group at the apex of the bend,
and clear density is observed for all parts of the molecule
including the phosphopantheteinyl moiety (Figure 2B). As
observed in other CoA complex structures, the adenine is
bound to the adenine ribose in an antiglycosidic torsion
angle. The ribose is in a 30-endo conformation, similar to
the conformation in complex with B. subtilis Sfp [13].
The 3-phospho-adenosine portion of CoA is tightly bound
through a combination of hydrophobic and hydrogen-
bonding interactions contributed by residues Lys89,
Lys91, Asn108, Arg47, and Arg86 (Figure 4). The latter
Figure 4. Ligand Binding of Human PPT-CoA Complex
(A) Detail of CoA and Mg binding to human PPT. The side chains of res-
idues involved in binding are drawn as sticks and labeled. The hypo-
thetical model for the side chain of Gln112 is represented in light
blue (see text for detail).
(B) Ligplot [37] representation of CoA and Mg binding with hydrogen
bonding interaction distances given in A˚ngstrom.3, November 2007 ª2007 Elsevier Ltd All rights reserved 1247
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Structure of Human ACP Synthasetwo basic residues play a key role by forming salt bridges
to the oxygen atoms of the 30-phosphate of the adenine
ribose. In Sfp, this role is played by Lys28 and Lys31,
but although Lys31 corresponds to Arg47 in PPT, the
equivalent residue to Lys28 is in fact Glu44 and, since it
is negatively charged, cannot contribute to phosphate
binding (Figure 2E). Since Glu44 is within hydrogen-bond-
ing distance to both Arg47 and Arg86, this change may be
necessary to stabilize the two highly charged Arg side
chains. The residue corresponding to Arg86 is Thr70 in
Sfp and, as the shorter side chain suggests, plays no
role in CoA binding. In addition, the N32 nitrogen of the
imidazole side chain of His111 binds to the 30-phosphate
group. The a-phosphate group of the pyrophosphate
moiety is held in place by interactions with the main-chain
amide of His111 and the side-chain hydroxyl of Ser110,
while the phosphopantheteinyl group is bound through in-
teractions with side and main chains of residues Glu181,
Gly190, Leu191, and Leu195. Magnesium is coordinated
by the a and b groups of the CoA pyrophosphate, the car-
boxylates of Asp129 and Glu181, and one water molecule
(Figure 4). Although the side chain of Gln112 is disordered,
modeling indicates that it could participate in Mg coordi-
nation by substituting its side-chain amide oxygen for
the ordered water. A sixth ligand for the Mg is not present
in the final crystallographic model; however, there is some
residual density that implies this position may be occupied
by a poorly ordered water molecule. The metal cation is
found in a solvent inaccessible area, shielded by protein
and CoA moieties. As found in many other Mg binding pro-
teins [24], PPT has, besides the inner coordination sphere
of the ligands described above, a hydrophobic outer shell
that is provided by residues Ile130, Met131, Tyr174, and
Trp177, thus creating an environment of high hydrophobic
contrast.
The cocrystallization experiments with PPT, CoA, Mg,
and a Ser2156Ala mutant of human cytosolic-FAS ACP
clearly showed that Mg was not present in this structure
(PDB ID: 2CG5) (Figure 3), unequivocally demonstrating
the nonessential nature of Mg for CoA binding. As
described above, the Ala2156 side chain pushes out the
water molecule that is bound to Glu181 in the PPT-CoA
structure. Elimination of the water causes Glu181 to adopt
a different side-chain conformation, which no longer con-
tributes to Mg binding. This water would presumably be
replaced by the Ser-OH acceptor group in a productive
PPT-CoA-ACP complex. Taken together, this indicates
CoA binding is mainly dependent on conserved residues
binding to the 30-adenosine phosphate (Arg47, Arg86,
and His111) as well as to the a-phosphate (Lys185,
Ser110, and His111) but not on binding of the divalent
cation. Protein ligands critically involved in Mg binding
are side chains of Glu181 and Asp129 as deduced from
the structural and kinetic data.
Kinetic Analysis of Human PPT
Residues likely involved in Mg and CoA binding were eval-
uated by determining the effects of site-directed mutage-
netic replacements on catalysis. Residues found to be1248 Chemistry & Biology 14, 1243–1253, November 2007 ª20highly conserved in the PPT family comprise in the human
enzyme Arg47, Arg86, His111, Gln112, Asp129, Glu181,
and Lys185. These residues were replaced as indicated
in Table 1.
Kinetic analyses (Table 1) revealed that replacement of
Glu181 (with Ala or Gln) or Asp129 (with Ala) has a relatively
small effect on Km for CoA but reduces the affinity for Mg
2+
by 20- to 40-fold and kcat by three orders of magnitude;
thus, catalytic efficiency is reduced by four orders of mag-
nitude. These findings, together with the crystallographic
data are consistent with a key role for Glu181 and
Asp129 side chains in Mg2+ binding. Though only partially
defined in the electron density maps, the crystallographic
analysis also implies that the side chain carbonyl of
Gln112 could be involved in Mg2+ binding but replacement
with Glu had little effect on the Km for Mg
2+, whereas kcat
was decreased by an order of magnitude. In contrast,
replacement of Glu181 with Gln elevated the Km for
Mg2+ 20-fold and decreased kcat > 300-fold. Exchange
of the Glu and Gln side chains at positions 112 and 181
in the double mutant elevated the Km for Mg
2+ > 200-
fold and reduced kcat 3 orders of magnitude, emphasiz-
ing the importance of the position of the two side chains
for proper coordination of Mg2+. Alanine replacement of
three residues involved in CoA binding, Arg47, Arg86, or
His111, resulted in a lowered affinity for CoA. However,
the affinity of these mutants for Mg2+ was also lowered,
suggesting that binding of CoA facilitates the subsequent
binding of Mg2+. This inference is supported by the crys-
tallographic data that show that Mg2+ is bound to CoA
via both the a and b groups of the pyrophosphate and
that in the crystal structure of the complex with ACP,
CoA is present but Mg2+ is not. Importantly, kcat for the
two arginine mutants was significantly elevated, suggest-
ing that, in the wild-type enzyme, the rate of release of the
30,50-ADP product may be limited by interaction of the two
guanidinium moieties with the 30-phosphate. Replace-
ment of Lys185 has no major effect on affinity for either
CoA or Mg but results in a reduction of kcat by three orders
of magnitude, consistent with the primary role of this res-
idue in the protonation of the a-phosphate that accom-
panies pyrophosphate cleavage.
The Catalytic Mechanism of Human PPT
Based on the structural and functional data obtained, we
propose the following catalytic mechanism for human
PPT (Figure 5): after initial CoA and Mg binding, ACP com-
pletes the complex. A proton is abstracted from the ACP-
Ser-hydroxyl group by Glu181, facilitated by a helix-dipole
effect from the a2 helix on ACP. The resulting ACP-Ser-hy-
droxylate carries out a nucleophilic attack on the b-phos-
phate of CoA, and after charge migration over the a-phos-
phate and protonation by Lys185, the pyrophosphate is
cleaved, and the products dissociate from the enzyme.
A rate limiting step is likely to be the dissociation of the
30,50-ADP product from the enzyme, indicated by the
significantly higher Vmax values obtained for mutants
Arg47Ala and Arg86Ala, which are involved in binding
this portion of the CoA molecule. Besides the structural07 Elsevier Ltd All rights reserved
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Structure of Human ACP SynthaseTable 1. Kinetic Properties of Human PPT and Selected Active-Site Mutants
PPT Varied Ligand Km (mM) kcat (min
1) kcat/Km (min
1 mM1)
WT Mg2+ 0.44 ± 0.04 14.4 ± 0.4 32.7
D129A 4.6 ± 0.3 0.0042 ± 0.0005 0.001
H111A 34.5 ± 5.6 7.3 ± 0.6 0.21
R47A 3.3 ± 1.0 48.0 ± 6.6 14.5
R86A 15 ± 3 72.0 ± 5.9 4.8
K185A 1.1 ± 0.1 0.018 ± 0.0004 0.016
E181A 18.3 ± 0.7 0.023 ± 0.0007 0.001
E181Q 7.6 ± 4.6 0.039 ± 0.005 0.005
Q112E 0.75 ± 0.24 1.32 ± 0.21 1.76
E181Q, Q112E 104.1 ± 51 0.019 ± 0.004 0.0002
WT C2-CoA 0.0249 ± 0.003 14.4 ± 0.73 578
D129A 0.142 ± 0.035 0.0059 ± 0.0001 0.04
H111A 0.095 ± 0.033 6.1 ± 1.3 64.2
R47A 0.076 ± 0.0038 34.0 ± 1.2 447
R86A 0.399 ± 0.041 58.4 ± 3.8 146
K185A 0.0247 ± 0.0036 0.015 ± 0.0004 0.6
E181A 0.0454 ± 0.0038 0.043 ± 0.0015 0.9
E181Q 0.081 ± 0.0013 0.044 ± 0.0026 0.5
Q112E 0.047 ± 0.023 2.2 ± 0.73 46.8
E181Q, Q112E 0.093 ± 0.001 0.024 ± 0.004 0.2
Kinetic parameters for Mg2+ were determined at saturating concentrations of acetyl-CoA and vice versa.data observed in the complexes, the role of Glu181 and
Lys185 as key acid/base catalysts is strongly supported
by the observed significant loss of activity for the
Glu181Gln, Glu181Ala, and Lys185Ala mutant proteins.
In addition to being a key catalyst, Lys185 is also involved
in binding the a-phosphate, whereas Glu181 does not
contribute to CoA but to Mg binding. The function of
Asp129 is compatible with a role in Mg coordination
(indicated by a loss of activity for the Ala substitution)
but not in CoA binding. This proposed mechanism for
human and presumably all other eukaryotic group II
PPTs is similar to the suggested Sfp mechanism [12] but
significantly different from the sequence of catalytic steps
outlined for the group I PPT AcpS, where a metal-ion-ac-
tivated water molecule is proposed to abstract a proton
from the acceptor Ser-hydroxyl group [11]. This is further
supported by the significantly reduced pyrophosphate
cleavage activity for group II PPTs (five orders of magni-
tude) in the absence of an acceptor molecule.
In summary, our study reveals fundamental differences
in the active site of the group II human PPT and the group I
bacterial PPTs, not only in architecture, but also in the
reaction mechanisms. The group I PPTs have a divalent
cation coordinated by the CoA a-phosphate, an Asp and
a Glu residue, and three water ligands, one of which is
proposed to act as a catalytic base [10, 11]. In the group
II human PPT, the divalent cation is coordinated by theChemistry & Biology 14, 1243–125CoA a- and b-phosphates, as well as two to three protein
side chains and a water molecule. Uniquely in the group II
human PPT, a protein carboxylate side chain is directly in-
volved in catalysis. Recently, a novel class of anthranilate
compounds was reported as lead candidate for bacterial
group I PPT targets [25], and screening of these com-
pounds in a PPT binding assay did not indicate significant
interactions with the human enzyme (data not shown),
consistent with the observed fundamental differences in
ligand binding and reaction mechanisms between group
I and II PPTs. Finally, hydrophobic interactions appear to
play an important role in stabilizing the complex between
the group II human PPT and its cognate type I ACP,
whereas ionic interactions are more critical in stabilizing
complexes between the group I PPTs and their cognate
type II ACPs.
SIGNIFICANCE
Cytosolic FAS has been discussed as a potential
target for the development of drugs for the treatment
of obesity and cancer [26, 27]. Thus, inhibitors of the
human PPT that would block the formation of a func-
tional holo-FAS might also be considered useful in
this regard. Surprisingly, however, mammals appear
to use a single PPT for the posttranslational modifica-
tion of the ACP domain of the cytosolic FAS and at3, November 2007 ª2007 Elsevier Ltd All rights reserved 1249
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Structure of Human ACP SynthaseFigure 5. Proposed Reaction Mecha-
nism for Human PPT
Residue E181 is the acid/base catalyst that
abstracts a proton from Ser2156 of ACP, and
cleavage of the pyrophosphate bond is
achieved after charge migration and proton-
ation of the a-phosphate likely achieved
through Lys185, resulting in dissociation of
the products from PPT.least two other proteins: the ACP component of a
mitochondrial FAS [22, 28–32] that is involved in the
synthesis of the lipoyl moieties required for the post-
translational modification of several key mitochon-
drial enzymes [33] and the aminoadipate semialde-
hyde dehydrogenase involved in lysine degradation
[2]. Therefore, anti-human-PPT agents would be ex-
pected to impact lipid synthesis, mitochondrial me-
tabolism and amino acid metabolism and are unlikely
to find therapeutic application. Nevertheless, group I
prokaryotic PPTs are being investigated as possible
targets for the development of new antibacterial
agents that could inhibit the production of bacterial li-
popolysaccharides and membrane lipids [8, 34]. So it
will be important to establish that these agents exhibit
high selectivity and do not target the human PPT. Our
study reveals fundamental differences in the active
site of the group II humanPPT and the group I bacterial
PPTs, not only in architecture but also in the mecha-
nism of interaction with the CoA, divalent cation, and
apoACP. This information could be exploited in the
design of inhibitors that target specifically the bacte-
rial group I PPTs.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Human PPT
and the ACP Domain of FAS
A construct encoding human PPT (template was obtained from the
MGC clone collection) was cloned by PCR into a pCOEX1 vector,
resulting in an N-terminally His6-tagged variant with a TEV protease
site. The construct was expressed in the phage-resistant E. coli
expression strain BL21(DE3)-R3 in TB medium supplemented with
34 mg/ml chloramphenicol. High-level soluble protein production was1250 Chemistry & Biology 14, 1243–1253, November 2007 ª20achieved by IPTG induction (1 mM) at 25C for 4 hr. Cells were
disrupted in a high-pressure homogenizer followed by sonication, nu-
cleic acids were precipitated by addition of polyethyleneimine (0.15%),
and the resulting cell lysate was centrifuged for 20 min at 40,000 3 g.
The clarified supernatant was filtered and then subjected to immobi-
lized metal affinity chromatography (Ni-NTA resin, QIAGEN) and eluted
in 250 mM imidazole, 500 mM NaCl, 50 mM HEPES (pH 7.5), 5% glyc-
erol. This was followed by a final gel filtration chromatographic step on
a Superdex 200 HiLoad 26/60 column (GE Healthcare, Uppsala, Swe-
den). Protein was purified in 10 mM HEPES (pH 7.5), containing 2mM
TCEP, 5% (w/v) glycerol, and concentrated to 20 mg/ml by using
a 30,000 kDa MW cutoff Amicon Ultra concentration device (Millipore,
Bedford, MA), resulting in a homogenous and pure protein preparation.
The experimentally determined mass by ESI-TOF mass spectrometry
(Agilent LC-MSD TOF) was in agreement to the predicted mass value.
A construct encoding residues 2117–2205 of the human FAS together
with a tev-cleavable N-terminal His6 tag was expressed in E. coli, and
the apoprotein purified as described previously [8]. The apoACP was
used for crystallization without cleavage of the N-terminal tag.
PPT Mutagenesis
PPT point mutations were generated with QuickChange XL site-
directed mutagenesis kit (Stratagene, USA) and wild-type human
PPT cDNA expression plasmid as DNA template. Appropriate
mutant primers were designed and mutagenesis carried out according
to the manufacturer’s instructions. Authenticity of all mutants was
confirmed by DNA sequencing.
Expression and Purification of PPT
For activity measurements, WT and mutants were expressed in E. coli
BL21 (DE3) with TB medium containing 34 mg/ml chloramphenicol in
4 3 500 ml cultures, each in 2 l flasks. Cells were grown at 37C to a
density corresponding to A600nm of 2, transferred to 25C, and then
expression was induced for 4 hr by the addition of 1 mM IPTG. Cells
were lysed in 50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 10 mM imidaz-
ole, 2 mM mercaptoethanol, 10% glycerol, containing protease inhib-
itors (leupeptin 5mg/ml, trans-epoxysuccinyl-LGB 10 mM, pepstatin
1 mg/ml, and antitrypsin 5 mg/ml) with a high-pressure microfluidizer,07 Elsevier Ltd All rights reserved
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apoPPT PPT + CoA PPT + ACP + CoA
PDB ID 2BYD 2C43 2CG5
Space group P212121 P212121 P3221
Unit cell a = 63.78 A˚, b = 69.95 A˚,
c = 71.24 A˚
a = 65.59 A˚, b = 68.96 A˚,
c = 70.75 A˚
a = b = 69.36 A˚,
c = 184.7 A˚
No. of unique reflection 21391 19791 14864
Resolution 47.5–2.00 (2.10–2.00) 32.8–1.93 (2.02–1.93) 34.7–2.70 (2.80–2.70)
Completeness (%) 96.4 (77.6) 80.3 (29.2) 99.9 (100)
Redundancy 6.6 (4.0) 5.0 (0.7) 10.4 (10.6)
I/s 11.8 (2.23) 16.5 (3.59) 17.9 (3.35)
Rint 0.128 (0.578) 0.084 (0.245) 0.090 (0.582)
Rcryst/Rfree 0.176/0.242 0.161/0.219 0.195/0.247
Rmsd bond length (A˚) 0.010 0.017 0.013
Rmsd bond angle () 1.28 1.66 1.50
No. protein atoms 2315 2276 2638
No. hetero atoms, ions 9 50 46
No. water molecules 189 180 24
Highest resolution shell indicated in parentheses.and the extract was centrifuged at 214,000 3 g, 90 min. The super-
natant was filtered through a 0.45 m membrane, and the enzyme was
purified on a column (6 ml) of NiNTA.
The bound PPT was eluted with 50 mM Tris-HCl (pH 7.5), 500 mM
NaCl, 250 mM imidazole, 2 mM mercapto EtOH, 10% glycerol, and
dialyzed overnight against 50 mM Tris-HCl (pH 7.5)/1 mM DTT/10%
glycerol. Further purification was achieved by anion exchange
chromatography on a column (6 ml) of Resource Q (Amersham Phar-
macia) equilibrated with 50 mM Tris-HCl (pH 7.5)/1 mM DTT/10% glyc-
erol and eluted with a gradient of NaCl (0–0.25M) in the same buffer.
The proteins were dialyzed against 50 mM Tris-HCl (pH 7.5)/0.1 M
NaCl/1 mM DTT/10% glycerol, homogeneity was confirmed by
SDS-PAGE on 10% acrylamide gels, and protein concentration was
determined from A280 nm by using extinction coefficients estimated
from A280 nm with the ProParam tool at http://www.expasy.ch/
tools/protparam.html.
PPT Kinetics
Mutant PPT activities were assayed at 37C in 83 mM Tris-HCl buffer
(pH 7) containing 100 mM apo-ACP, MgCl2 and [1-
14C]acetyl-CoA; final
volume was 30 ml. The specific radioactivity of the [1-14C]acetyl-CoA
substrate, the amount of enzyme used, and the duration of the incuba-
tion were varied, according to the activity of the particular mutant, to
provide sufficient yield of radiolabeled product and ensure that
steady-state conditions always prevailed. Reactions were stopped
by the addition of trichloroacetic acid (final concentration, 10%); bo-
vine serum albumin (0.4 mg) was added as coprecipitant, and the pre-
cipitate containing [1-14C]acetyl-S-ACP was washed three times with
trichloroacetic acid, dissolved in 330 ml of 6 M guanidine hydrochloride
and assayed for radioactivity by liquid scintillation spectrometry. One
unit of activity corresponds to 1 nmol product formed per min. Kinetic
parameters are the mean ± SD values from six different methods, de-
rived with EnzymeKinetics (Trinity Software). CoA pyrophosphatase
activity was assayed in the absence of an ACP acceptor. Unreacted
CoA was derivatized with DTNB and separated from the 30,50-ADP
product by anion exchange chromatography on a HiTrap Q HR column
eluted with a gradient of NaCl, 0–1 M in 20 mM BisTris (pH 7).Chemistry & Biology 14, 1243–1253Crystallization and Structure Determination
Initial crystals were obtained from several coarse screen conditions
that contained around 20% PEG, 0.20 M salt and had slightly acidic
pH. These were further optimized, and conditions were sorted based
on diffraction properties. Eventually, long rod-like crystals with aver-
age dimensions 0.1 3 0.1 3 0.6 mm3 could be obtained from 14%
PEG3350 and 0.05 M H3Cit/Na3Cit (pH 5.7). Since it was established
that no suitable molecular replacement model exists and crystals
from selenomethionine-labeled protein could not be obtained, a crystal
was soaked in a cryoprotectant solution consisting of the mother
liquor, 20% PEG400 and 0.5 M KBr, and flash frozen by plunging
into liquid nitrogen. Datasets were collected at the PXII beamline at
the Swiss Light Source by using 0.9198 A˚ radiation (peak wavelength
determined from a fluorescence scan). Data were processed with XDS,
and different scans were scaled together with XSCALE. Data collection
and refinement statistics are given in Table 2.
Strong anomalous signal was obtained, and bromide atoms were
located with SHELXD. After phase calculation and density modification
by SHELXE, ARP/wARP was started that resulted in an initial trace,
which was completed manually and recycled for ARP/wARP. After sev-
eral cycles, a virtually complete trace could be obtained. Refinement
was completed with refmac5.
Crystals of the PPT-CoA complex were obtained by cocrystallizing
the protein with 5 mM CoA in the presence of 20 mM MgCl2. Initial
screening was repeated and diffraction quality crystal were obtained
from 2.0 M NaCl and 10% PEG6000. PPT was also cocrystallized
with equimolar amount of Ser2156Ala ACP, in the presence of
2.5 mM coenzyme A and 12 mM MgCl2. Trigonal pyramids could be
obtained from 0.4 M NH4H2PO4. Data for both complexes were
collected on a Rigaku FR-E rotating anode equipped with Osmic-HR
multilayer optics and a Rigaku HTC image plate detector. Datasets
were processed with XDS, and the structures were solved with molec-
ular replacement by using the apoprotein as a search model. For the
ACP complex, ACP was built manually into the electron density. The
structures were refined with refmac5.
Please note that the sequence numbering between the PDB files and
the structure discussed in this text is offset by +10., November 2007 ª2007 Elsevier Ltd All rights reserved 1251
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